1. Home
  2. APLM vs SAG Comparison

APLM vs SAG Comparison

Compare APLM & SAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APLM
  • SAG
  • Stock Information
  • Founded
  • APLM 2016
  • SAG 1975
  • Country
  • APLM United States
  • SAG Singapore
  • Employees
  • APLM N/A
  • SAG N/A
  • Industry
  • APLM Blank Checks
  • SAG
  • Sector
  • APLM Finance
  • SAG
  • Exchange
  • APLM Nasdaq
  • SAG NYSE
  • Market Cap
  • APLM 7.7M
  • SAG 7.1M
  • IPO Year
  • APLM N/A
  • SAG 2024
  • Fundamental
  • Price
  • APLM $6.71
  • SAG $0.72
  • Analyst Decision
  • APLM Strong Buy
  • SAG
  • Analyst Count
  • APLM 2
  • SAG 0
  • Target Price
  • APLM $425.00
  • SAG N/A
  • AVG Volume (30 Days)
  • APLM 42.6K
  • SAG 7.8M
  • Earning Date
  • APLM 04-15-2025
  • SAG 12-19-2024
  • Dividend Yield
  • APLM N/A
  • SAG N/A
  • EPS Growth
  • APLM N/A
  • SAG N/A
  • EPS
  • APLM N/A
  • SAG 0.21
  • Revenue
  • APLM $2,101,000.00
  • SAG $56,387,000.00
  • Revenue This Year
  • APLM N/A
  • SAG N/A
  • Revenue Next Year
  • APLM N/A
  • SAG N/A
  • P/E Ratio
  • APLM N/A
  • SAG $3.89
  • Revenue Growth
  • APLM 70.54
  • SAG N/A
  • 52 Week Low
  • APLM $6.20
  • SAG $0.47
  • 52 Week High
  • APLM $63.00
  • SAG $8.27
  • Technical
  • Relative Strength Index (RSI)
  • APLM 43.33
  • SAG N/A
  • Support Level
  • APLM $6.20
  • SAG N/A
  • Resistance Level
  • APLM $8.00
  • SAG N/A
  • Average True Range (ATR)
  • APLM 1.37
  • SAG 0.00
  • MACD
  • APLM -0.18
  • SAG 0.00
  • Stochastic Oscillator
  • APLM 9.44
  • SAG 0.00

About APLM Apollomics Inc.

Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

About SAG SAG HOLDINGS LTD

SAG Holdings Ltd engages in the business of distributing automotive and industrial spare parts with operations primarily based in Singapore, and global sales primarily generated from the Middle East and Malaysia. Its business is comprised of On-Highway Business serving the automotive sector and Off-Highway Business primarily servicing the marine, energy, mining, construction, agriculture, and oil and gas sectors. The On-Highway Business Segment supply genuine and aftermarket spare parts to customers through our Autozone retail outlets located in Singapore, as well as Malaysia. The Off-Highway Business Segment supply a wide range of components and spare parts for internal combustion engines with a strong focus on filtration products through Filtec.

Share on Social Networks: